NOTCH1 and adrenal cortex carcinoma: Additionally, Brontictuzumab, a humanized monoclonal antibody that binds to the NOTCH1 juxtamembrane negative regulatory region, was found to have antitumor efficacy in a subcohort of patients with NOTCH-activated ACC [204].